Type of Cancer
Multiple Myeloma
Phase
Division (Location)
Study ID
NCT#
Brief Description
Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.